Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Barsouk A, Aluru JS, Rawla P, et al. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci (Basel). 2023;11(2):42. doi: 10.3390/medsci11020042
   PubMedGoogle Scholar
• Chow LQM, Longo DL. Head and neck cancer. N Engl J Med. 2020;382(1):60–72. doi: 10.1056/NEJMra1715715
   PubMed Web of Science ®Google Scholar
• Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol. 1994;21(3):311–319.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127. doi: 10.1056/NEJMoa0802656
   PubMed Web of Science ®Google Scholar
• Guo Y, Luo Y, Zhang Q, et al. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: efficacy and safety results of the randomised, phase III CHANGE-2 trial. Eur J Cancer. 2021;156:35–45. doi: 10.1016/j.ejca.2021.06.039
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928. doi: 10.1016/S0140-6736(19)32591-7
   PubMed Web of Science ®Google Scholar
• Peyrade F, Borel C, Daste A, et al. Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes. Curr Opin Oncol. 2021 May 1;33(3):160–167. doi: 10.1097/CCO.0000000000000738
   PubMed Web of Science ®Google Scholar
• Burtness B, Rischin D, Greil R, et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score. J Clin Oncol. 2022;40(21):2321–2332. doi: 10.1200/JCO.21.02198
   PubMed Web of Science ®Google Scholar
• Hecht M, Hahn D, Wolber P, et al. Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. BMC Cancer. 2020;20(1):933. doi: 10.1186/s12885-020-07440-w
   PubMed Web of Science ®Google Scholar
• Chen TH, Pan YY, Lee TL, et al. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma. BMC Cancer. 2022;22(1):1336. doi: 10.1186/s12885-022-10440-7
   PubMed Web of Science ®Google Scholar
• Saâda-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605–1611. doi: 10.1093/annonc/mdx178
   PubMed Web of Science ®Google Scholar
• Huang Y, Yang L, Hu X. Comparison of second-line treatments for patients with platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and bayesian network meta-analysis. Cancers (Basel). 2022;14(18):4472. doi: 10.3390/cancers14184472
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulières D, Le Tourneau C, et al. pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–167. doi: 10.1016/S0140-6736(18)31999-8
   PubMed Web of Science ®Google Scholar
• Psyrri A, Fayette J, Harrington K, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol. 2023;34(3):262–274. doi: 10.1016/j.annonc.2022.12.008
   PubMed Web of Science ®Google Scholar
• Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. J Clin Oncol. 2023;41(12):2166–2180. doi: 10.1200/JCO.22.00332
   Google Scholar
• Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 81:45–51. doi: 10.1016/j.oraloncology.2018.04.008
   PubMed Web of Science ®Google Scholar
• Lien MY, Wang TH, Hsieh CY, et al. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival. Oral Oncol. 2021;119:105380. doi: 10.1016/j.oraloncology.2021.105380
   PubMed Web of Science ®Google Scholar
• Fasano M, Corte CMD, Liello RD, et al. Immunotherapy for head and neck cancer: present and future. Crit Rev Oncol Hematol. 2022;174:103679. doi: 10.1016/j.critrevonc.2022.103679
   PubMed Web of Science ®Google Scholar
• Addeo R, Ghiani M, Merlino F, et al. CheckMate 141 trial: all that glitters is not gold. Expert Opin Biol Ther. 2019;19(3):169–171. doi: 10.1080/14712598.2019.1570498
   PubMed Web of Science ®Google Scholar
• Karpathiou G, Vincent M, Dumollard JM, et al. PD-L1 expression in head and neck cancer tissue specimens decreases with time. Pathol Res Pract. 2022;237:154042. doi: 10.1016/j.prp.2022.154042
   PubMed Web of Science ®Google Scholar
• Haddad RI, Seiwert TY, Chow LQM, et al. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10(2):e003026. doi: 10.1136/jitc-2021-003026
   PubMed Web of Science ®Google Scholar
• De Keukeleire SJ, Vermassen T, Deron P, et al. Concordance, correlation, and clinical impact of standardized PD-L1 and TIL scoring in SCCHN. Cancers (Basel). 2022;14(10):2431. doi: 10.3390/cancers14102431
   PubMed Web of Science ®Google Scholar